Fulcrum Therapeutics, Inc.
USD3.14
-3.28 (-51.09%)
CEO
Alexander C. Sapir
IPO Date
2019-07-18
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
US
Open
$3.11
Prev. Close
$6.42
Day Low
$2.83
Day High
$3.26
52W Low
$2.83
52W High
$15.74
Market Cap
$0.17B
Volume
32.77M
| 0 |
| $0.00 |
| 4 Feb 2026 | Gould Robert J | director | S-Sale | Disposed | 15,000 | $10.87 |
| 4 Feb 2026 | Musso Alan A | Chief Financial Officer | A-Award | Acquired | 170,000 | $10.72 |
| 4 Feb 2026 | Oltmans Curtis Gale | Chief Legal Officer | A-Award | Acquired | 170,000 | $10.72 |
| 4 Feb 2026 | Gould Robert J | director | S-Sale | Disposed | 15,000 | $10.72 |
| 4 Feb 2026 | Tourangeau Greg | Principal Accounting Officer | A-Award | Acquired | 57,000 | $10.72 |
| 4 Feb 2026 | Sapir Alex | director, officer: See Remarks | A-Award | Acquired | 650,000 | $10.72 |
| 6 Jan 2026 | Gould Robert J | director | S-Sale | Disposed | 15,000 | $11.87 |
| 17 Dec 2025 | Oltmans Curtis Gale | Chief Legal Officer | S-Sale | Disposed | 3,452 | $12.92 |